Tag Archives: TYRUKO Availability Marks Major Milestone in Affordable MS Care and Sandoz Biosimilar Leadership

Sandoz Expands US Biosimilar Portfolio with TYRUKO for Relapsing Multiple Sclerosis and Crohn’s Disease

(IN BRIEF) Sandoz has announced the US availability of TYRUKO® (natalizumab-sztn), the first FDA-approved biosimilar to Tysabri® for treating relapsing forms of multiple sclerosis and Crohn’s disease. Developed by Polpharma Biologics, TYRUKO® is clinically equivalent to its reference product and … Read the full press release